

- **Name:** Han Sang Kim
  - **Current Position & Affiliation:** Assistant Professor  
Yonsei Cancer Center  
Yonsei University College of Medicine
  - **Country:** Republic of Korea
- 

- **Educational Background:**

2002.03-2008.02	M.D.	Yonsei University
2008.03-2010.08	M.S.	Yonsei University
2012.03-2018.02	Ph.D.	Yonsei University (Physician-Scientist Program)

- **Professional Experience:**

2018.03-2019.02	Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea	Clinical Fellow
2019.03-2020.02	Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea	Clinical Assistant Professor
2020.03-at present	Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea	Assistant Professor

- **Professional Organizations:**

2021.03-at present	Colorectal cancer	KSMO (Korean Society Medical Oncology)
2022.03-at present	Academic committee	KSEV (Korean Society for Extracellular Vesicles)
2021.09-at present	Planning committee	KOGO (Korea Genome Organization)

- **Main Scientific Publications:**

- Hoshino A\*, **Kim HS\***, Linda Bojmar\*, Gyan\*, Jones D, Matei I, Jarnagin WR, Lyden D et al. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. *Cell* 2020;182(4):1044-1061. \*co-first
- Kim S\*, **Kim HS\***, Kim E, Lee MG, Shin E, Paik S, Kim S. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information. *Ann Oncol.* 2018;29(4):1030-1036. \*co-first
- Kim HS\***, Cheon JH\*, Jung ES\*, Park J, Aum S, Park SJ, Eun S, Lee J, R  ther U, Yeo GS, Ma M, Park KS, Naito T, Kakuta Y, Lee JH, Kim WH, Lee MG. A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD. *Gut.* 2017;66(11):1926-1935. \*co-first
- Kim HS\***, Jung M\*, Kang HN\*, Kim H, Park CW, Kim SM, Shin SJ, Kim SH, Kim SG, Kim EK, Yun MR, Zheng Z, Chung KY, Greenbowe J, Ali SM, Kim TM, Cho BC. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. *Oncogene.* 2017;36(23):3334-3345. \*co-first
- Kim KH\*, **Kim HS\***, Kim SC\*, Kim D, Kim YB, Chung HC, Rha SY. Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells. *Front Oncol.* 2020;10:562284. \*co-first
- Zhang H, Freitas D\*, **Kim HS\***, Fabijanic K, Li Z, Reis CA, Lyden D et al. Identification of novel nanoparticles and distinct exosome subsets via asymmetric-flow field-flow fractionation. *Nat Cell Biol.* 2018;20(3):332-343. \*co-second